Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.
Journal: bioRxiv : the preprint server for biology
Published: July 09, 2025
Multiomic Immune Profiling of Pediatric Transplant Recipients Identifies Cell States Associated with Vaccine Response.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: June 05, 2025
Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell State.
Journal: bioRxiv : the preprint server for biology
Published: March 13, 2023
Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state.
Journal: The Journal of clinical investigation
Published: November 09, 2022
MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation.
Journal: Cancers
Published: September 02, 2021
Alveolar rhabdomyosarcoma presenting as a pleural effusion: An atypical presentation of a malignancy.
Journal: Pediatric pulmonology
Published: May 11, 2020
COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation.
Journal: Pediatric blood & cancer
Published: April 16, 2020
ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
Journal: Nature communications
Published: January 08, 2019
MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.
Journal: Cancer discovery
Published: September 04, 2017
Corrigendum: Small genomic insertions form enhancers that misregulate oncogenes.
Journal: Nature communications
Published: June 02, 2017
Last Updated: 09/26/2026